Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Challenges and opportunities of mRNA vaccines against SARS-CoV-2 : a multidisciplinary perspective / / Siguna Mueller
| Challenges and opportunities of mRNA vaccines against SARS-CoV-2 : a multidisciplinary perspective / / Siguna Mueller |
| Autore | Mueller Siguna |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2023] |
| Descrizione fisica | 1 online resource (460 pages) |
| Disciplina | 362.1962414 |
| Soggetto topico |
COVID-19 (Disease) - Prevention
COVID-19 vaccines |
| ISBN |
9783031189036
9783031189029 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion. |
| Record Nr. | UNINA-9910640386603321 |
Mueller Siguna
|
||
| Cham, Switzerland : , : Springer, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Trends in MRNA Vaccine Research
| Trends in MRNA Vaccine Research |
| Autore | Szabo Gabor Tamas |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2025 |
| Descrizione fisica | 1 online resource (428 pages) |
| Altri autori (Persone) |
PardiNorbert
FischerJános KleinChristian ChildersWayne E |
| Collana | Trends in Drug Discovery Series |
| Soggetto topico |
COVID-19 vaccines
Messenger RNA |
| ISBN |
9783527838387
3527838384 9783527838394 3527838392 9783527838370 3527838376 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover -- Title Page -- Copyright -- Contents -- Preface -- Preface from the Volume Editors -- Part I How mRNA Vaccines Work -- Chapter 1 A Historical Overview on mRNA Vaccine Development -- 1.1 Introduction -- 1.2 The Path of mRNA as an Unstable and Toxic Product to a New Class of Medicine -- 1.2.1 The Discovery and In Vitro Production of mRNA -- 1.2.2 The Inflammatory Nature of mRNA -- 1.3 How Studying Lipid Bilayer Structures in Cell Membranes Gave Rise to the Eventual Development of Lipid Nanoparticles for RNA Delivery -- 1.3.1 From Biological Cell Membranes to Liposomal Drugs -- 1.3.2 Ionizable Lipid Nanoparticles for Systemic Delivery of Nucleic Acids -- 1.4 The Journey of Developing Clinical mRNA Vaccines -- 1.5 Concluding Remarks -- References -- Chapter 2 Immune Responses to mRNA Vaccine -- 2.1 Introduction -- 2.2 Innate Sensing of RNA Molecules -- 2.3 Innate Immune Response to mRNA Vaccines -- 2.3.1 Innate Immune Response in Humans -- 2.3.2 Tissue Innate Immune Response in Mice -- 2.4 mRNA Design and Innate Immunity -- 2.4.1 Cap -- 2.4.2 Untranslated Regions -- 2.4.3 Poly(A) -- 2.4.4 Coding Sequence -- 2.5 Optimization and Production of mRNA for an Adequate Innate Immune Response |
| Record Nr. | UNINA-9911019785503321 |
|
Szabo Gabor Tamas
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
